KOSPIChemicals002760

Bolak

₩1,022▲ 0.69%2026-11-18 close
Market Cap
₩61.2B
Turnover
₩52,709,377
Volume
50K
Shares out.
59.9M
PER
28.4×
PBR
1.2×
EPS
₩36
Dividend Yield
0.69%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩7 per share · Prices as of the 2026-11-18 close

01

Report overview

Back in the Black, but Revenue Recovery Is Still Pending

Bolak returned to operating and net profit in 2025 and its operating profit has risen for three straight quarters since Q1 2026, but Q3 2026 revenue of KRW 11.4 billion fell year on year, so whether sales recover is the key point to watch.

  1. 1

    Operating profit in 2025 was KRW 2.23 billion, turning positive from an operating loss of KRW 1.79 billion in 2024, and revenue rose for two consecutive years to KRW 50.1 billion.

  2. 2

    Q3 2026 revenue was KRW 11.4 billion, down 4.3% year on year, and operating profit was KRW 701 million, down 28.8% year on year, although operating profit has grown for three consecutive quarters since Q1 2026.

  3. 3

    Q3 2026 net profit attributable to controlling shareholders was KRW 653 million, down 35.9% year on year, and the four-quarter total from Q4 2025 to Q3 2026 is KRW 2.16 billion.

  4. 4

    Chairman Chung Ki-ryun, the largest shareholder, held a 26.38% stake as of November 2, 2026 after open-market purchases, and the board approved a KRW 1 billion treasury share trust contract on November 3, 2026.

  5. 5

    Food additive raw materials account for roughly half of sales, while the pharmaceutical raw materials business faces tighter regulation and higher compliance costs.

02

Business structure

Bolak began as a food additive maker centered on flavors in the 1960s and now runs two businesses, food additives and pharmaceutical raw materials.

In 2025, food additive raw materials generated KRW 25.2 billion, or 50.28% of sales, while pharmaceutical raw materials generated KRW 9.3 billion, or 18.49% (IB Tomato report). The food additive unit centers on flavor products such as food flavors, flavor bases for confectionery, and flavor powders.

The company said it is focusing on higher-quality additives suited to the growth of imported processed foods and ready-made meals (HMR).

The pharmaceutical raw materials unit develops herbal raw materials based on a processing system for natural-derived materials and produces them at a GMP facility (NICE D&B company analysis, 2022).

Pipeline items reported include improving quality and expanding supply of CMC calcium and CMC sodium, and follow-on research on an anticancer API. Food additive orders are made to order, so results depend on order volume, according to a company official (The Fact, May 2026).

R&D spending in 2025 was KRW 1.14 billion, or 2.28% of sales (IB Tomato report). A 2025 results report noted that domestic sales, a large share in both core businesses, were declining.

Unlike large petrochemical groups such as LG Chem or Lotte Chemical, which mass-produce commodity chemicals, Bolak has a much smaller scale and a materials business tied to food and medicine uses.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩11.9B₩1B8.2%
2025Q4₩11.4B₩50,000,1680.4%
2026Q1₩11.2B₩600M5.0%
2026Q2₩12.5B₩700M5.5%
2026Q3₩11.4B₩700M6.1%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩48.4B₩3.3B₩3.1B6.8%6.3%25.9%
2023₩46.8B₩500M₩900M1.1%1.8%18.8%
2024₩47.6B-₩1.8B-₩1.5B−3.8%−3.2%27.1%
2025₩50.1B₩2.2B₩2.3B4.4%4.8%21.6%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

Annual results started at revenue of KRW 48.4 billion and operating profit of KRW 3.28 billion in 2022, then fell to a low in 2023, with revenue of KRW 46.8 billion (down 3.4% year on year) and operating profit of KRW 506 million (down 84.6%).

In 2024, revenue rose 1.8% to KRW 47.6 billion, but the company posted an operating loss of KRW 1.79 billion, turning from profit to loss, with an operating margin of -3.8%.

Revenue in 2025 rose 5.3% to KRW 50.1 billion, the second straight year of growth since 2024, and 2025 was the largest year of 2022 to 2025 by revenue. Operating profit returned to KRW 2.23 billion in 2025 with a 4.4% operating margin, a recovery from 1.1% in 2023 and -3.8% in 2024, though still below the 6.8% of 2022.

Net profit attributable to controlling shareholders swung to KRW 2.34 billion in 2025, and total net profit including non-controlling interests was also reported at KRW 2.34 billion. Operating cash flow rose from KRW 900 million in 2024 to KRW 7.17 billion in 2025.

At year-end 2025, total equity was KRW 4.87 billion, total liabilities were KRW 1.05 billion, and the debt ratio was 21.6%, down from 27.1% in 2024.

On a quarterly basis, Q3 2025 revenue of KRW 11.9 billion and operating profit of KRW 984 million fell in Q4 2025 to revenue of KRW 11.4 billion and operating profit of KRW 50 million, down 94.9% from the prior quarter, with net profit attributable to controlling shareholders of KRW 30.53 million.

A company official attributed such volatility to order-based production, where results depend on order volume.

Q1 2026 revenue was KRW 11.2 billion, operating profit rose to KRW 557 million, and net profit attributable to controlling shareholders reached KRW 543 million, while The Fact reported that revenue fell 14.11% year on year in that quarter.

Q2 2026 revenue rose 11.5% quarter on quarter to KRW 12.5 billion, with operating profit of KRW 683 million and net profit attributable to controlling shareholders of KRW 931 million.

Q3 2026 revenue of KRW 11.4 billion was down 8.6% quarter on quarter and 4.3% year on year, with operating profit of KRW 701 million (down 28.8% year on year) and net profit attributable to controlling shareholders of KRW 653 million (down 35.9% year on year). Operating profit has grown for three consecutive quarters, but revenue fell again after a rebound in Q2.

05

Industry analysis

Demand for food additives is supported by the growth of imported processed foods and ready-made meals (HMR), according to an IB Tomato report. By contrast, the pharmaceutical raw materials business faces tighter regulation and higher compliance costs, which raises doubts about sustained growth.

Capital has flowed toward market-leading sectors. During a rally in May 2026 when the KOSPI moved above 7,400, money moved into semiconductors, artificial intelligence and power equipment, while Bolak had weak links to that trend (The Fact report).

A company official said the stock does not move with the index in strong markets but also does not suffer much when the index is weak. The share price has been read as a phase in which operating fundamentals came into focus after the 'LG family link' theme faded (The Fact).

An industry source assessed that the theme premium had largely run out. Competitively, Bolak is a small maker in niche food and medicine materials, unlike large petrochemical groups. Both core businesses depend heavily on domestic sales, making them sensitive to domestic demand and drug regulation.

R&D spending fell to 2.28% of sales from 2.46% a year earlier (IB Tomato report), a metric that can be tracked against future annual reports.

06

Outlook

According to an IB Tomato report from 2026, the company said it has no new business investment plans this year and will continue its existing businesses.

Its treasury share acquisition began with a KRW 1.5 billion trust disclosed on July 6, 2026, which acquired 1,512,435 shares and was terminated early on November 3, 2026 after completion (Digital Today).

A Bloter report said the company had originally planned phased purchases through early 2027 but reached its target volume ahead of schedule. A new KRW 1 billion trust contract was approved by the board on November 3, 2026, running from November 4, 2026 to May 3, 2027.

Under this contract, the company plans to acquire 1,019,367 common shares and cancel all of them. Chairman Chung Ki-ryun increased his holding by 130,000 shares through open-market purchases between October 28 and November 2, 2026, bringing his stake to 26.38% as of November 2, 2026.

Director Hwang Bo Dae-ho also bought 9,000 shares on the open market, bringing his holding to 129,000 shares, or 0.21%, as of November 5, 2026. The pharmaceutical raw materials business faces higher compliance costs under tighter regulation, and whether it can keep growing will show up in upcoming annual results.

Food additive results depend on order volume, so whether Q4 2026 revenue holds near the KRW 11.4 billion of Q3 2026 is the next point to check. Q4 and full-year 2026 results should first appear in preliminary earnings announced in early 2027.

The 2026 annual report, the next regular filing, will show whether the operating margin exceeds 4.4% from 2025 and how the debt ratio moves.

07

Valuation

PER
28.4×
PBR
1.2×
ROE
4.4%
EPS
₩36
BPS
₩821
Dividend per share
₩7

Trailing earnings over the last four quarters total KRW 2.16 billion, a small base, so the valuation multiple is sensitive to changes in profit.

Total equity at the end of 2025 was KRW 4.87 billion, with the same amount attributable to controlling shareholders, and the market capitalization sits above that book value, meaning a premium over net assets. The dividend yield was also below the industry average in a 2024 market data compilation.

An industry source said in May 2026 that the premium from the family-link theme had largely faded, so how much the market prices in the profit recovery is the key question.

The KRW 1 billion treasury share purchase is small relative to market capitalization, and its effect on the share price can be observed as the trust runs. The next annual report, showing revenue recovery and the operating profit trend, provides the reference point for valuation.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Profit recovery trend

Operating profit swung from an operating loss of KRW 1.79 billion in 2024 to KRW 2.23 billion in 2025. It has risen for three consecutive quarters since Q1 2026, reaching KRW 683 million in Q2 and KRW 701 million in Q3. Operating cash flow in 2025 rose to KRW 7.17 billion.

Shareholder return actions

The company acquired 1,512,435 shares under a July 2026 trust and approved a new KRW 1 billion trust in November 2026 for 1,019,367 shares to be fully cancelled. The largest shareholder and a director have also made open-market purchases.

Balance sheet capacity

The debt ratio fell to 21.6% at the end of 2025 from 27.1% in 2024, with total liabilities of KRW 1.05 billion and total equity of KRW 4.87 billion. A limited debt burden gives room to absorb order declines or regulatory changes in the raw materials business.

09

Bear factors

Continued revenue decline

Q3 2026 revenue of KRW 11.4 billion fell 4.3% year on year. After a rebound to KRW 12.5 billion in Q2 2026, revenue dropped again in Q3, and the trend from Q2 2025 through Q1 2026 was also downward.

Thin margins and volatility

Operating margins were 1.1% in 2023, -3.8% in 2024 and 4.4% in 2025, all thin. Operating profit shrank to KRW 50 million in Q4 2025, and a company official said results depend on order volume under an order-based production model.

Flows and market neglect

During a rally led by semiconductors and artificial intelligence, Bolak had weak links to market leaders. An industry source said the theme premium had largely faded, and some observers see the valuation multiple as demanding for a small manufacturer with shrinking sales.

10

Risk factors

Regulation and pharmaceutical raw materials

The pharmaceutical raw materials business faces stricter regulation and rising compliance costs, which raise doubts about its growth. With this unit at 18.49% of sales, higher regulatory costs would directly affect margins. R&D spending falling to 2.28% of sales could also slow product upgrades.

Order volatility and domestic dependence

Food additives are made to order, so quarterly results swing with order volume. Domestic sales in both core businesses were also flagged as declining. Whether growth in imported processed foods and HMR turns into actual orders remains to be seen.

Share price flows and small-cap traits

Bolak drew attention in the past as a family-link theme stock, and that premium has largely faded according to industry sources. As a small-cap stock trading near the KRW 1,000 level, its price can move sharply with shifts in market flows. The largest shareholder's 26.38% stake also limits the free float, which shapes trading conditions.

11

What to watch next

  1. Early 2027

    Preliminary Q4 and full-year 2026 results. The checkpoints are whether Q4 revenue holds near Q3's KRW 11.4 billion and whether operating profit continues its three-quarter upward run. Exact timing should be confirmed through DART.

  2. Late March 2027

    Filing of the 2026 annual report, due by the statutory deadline. The checkpoints are whether the operating margin exceeds 4.4% from 2025, the regulatory cost and R&D trends, and the change in the debt ratio.

  3. May 3, 2027

    End of the KRW 1 billion treasury share trust contract period. The checkpoint is whether all 1,019,367 shares are acquired and fully cancelled.

12

Overall view

Bolak swung from a 2024 operating loss to a 2025 operating profit and positive net profit attributable to controlling shareholders, and its operating profit has risen for three consecutive quarters since Q1 2026.

Revenue grew for two straight years to KRW 50.1 billion in 2025, but Q3 2026 revenue of KRW 11.4 billion fell 4.3% year on year, so a sales recovery is not yet confirmed.

Positive factors include the profit recovery, treasury share purchases and cancellations, open-market buying by the largest shareholder and a director, and a debt ratio of 21.6% at the end of 2025.

Negative factors include quarterly volatility from order-based production, tighter regulation of pharmaceutical raw materials, declining domestic sales, and a share price that has lagged growth-sector leadership.

Trailing earnings over the last four quarters total KRW 2.16 billion, so whether a valuation above book value holds depends on how far the profit recovery continues. The next checkpoints are the preliminary 2026 full-year results expected in early 2027 and the 2026 annual report due by late March 2027.

Whether revenue recovers and whether the operating margin holds above 2025's 4.4% are the central questions, and the treasury share trust runs through May 3, 2027. This report summarizes disclosed facts and press reports without investment recommendations.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. digitaltoday.co.kr
  2. comp.fnguide.com
  3. vegannews.co.kr
  4. ssl.pstatic.net
  5. digitaltoday.co.kr
  6. google.com
  7. ibtomato.com
  8. digitaltoday.co.kr
  9. edaily.co.kr
  10. edaily.co.kr
  11. digitaltoday.co.kr
  12. digitaltoday.co.kr
  13. bloter.net
  14. pflow.keywordegg.com
  15. m.news.nate.com
  16. kr.investing.com
  17. judal.co.kr
  18. investing.com

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis